Selected article for: "cell surface and host pathogen"

Author: Hwang, Hye Suk; Chang, Mincheol; Kim, Yoong Ahm
Title: Influenza–Host Interplay and Strategies for Universal Vaccine Development
  • Cord-id: 7y42zng9
  • Document date: 2020_9_20
  • ID: 7y42zng9
    Snippet: Influenza is an annual epidemic and an occasional pandemic caused by pathogens that are responsible for infectious respiratory disease. Humans are highly susceptible to the infection mediated by influenza A viruses (IAV). The entry of the virus is mediated by the influenza virus hemagglutinin (HA) glycoprotein that binds to the cellular sialic acid receptors and facilitates the fusion of the viral membrane with the endosomal membrane. During IAV infection, virus-derived pathogen-associated molec
    Document: Influenza is an annual epidemic and an occasional pandemic caused by pathogens that are responsible for infectious respiratory disease. Humans are highly susceptible to the infection mediated by influenza A viruses (IAV). The entry of the virus is mediated by the influenza virus hemagglutinin (HA) glycoprotein that binds to the cellular sialic acid receptors and facilitates the fusion of the viral membrane with the endosomal membrane. During IAV infection, virus-derived pathogen-associated molecular patterns (PAMPs) are recognized by host intracellular specific sensors including toll-like receptors (TLRs), C-type lectin receptors, retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs), and nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) either on the cell surface or intracellularly in endosomes. Herein, we comprehensively review the current knowledge available on the entry of the influenza virus into host cells and the molecular details of the influenza virus–host interface. We also highlight certain strategies for the development of universal influenza vaccines.

    Search related documents:
    Co phrase search for related documents
    • adaptive immune response and low expression: 1, 2
    • adaptive immune response and lrr leucine rich repeat: 1
    • adaptive immune response and lung damage: 1, 2, 3, 4, 5, 6
    • adaptive immune response and lung environment: 1, 2, 3
    • adaptive immune response and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • adaptive immune response and lung pathology: 1, 2, 3, 4
    • adaptive immune response and lung resident: 1
    • adaptive immune response and lung tissue: 1, 2, 3, 4, 5, 6, 7
    • adaptive immune response and lymph node: 1, 2, 3, 4, 5, 6
    • adaptive immune response and lymph node drain: 1
    • adaptive immune response and lysosomal degradation: 1
    • adaptive immune response and mabs monoclonal antibody: 1
    • adaptive immunity and administration formulation: 1, 2
    • adaptive immunity and low expression: 1, 2, 3, 4
    • adaptive immunity and low income: 1, 2
    • low income and lung damage: 1, 2, 3, 4
    • low income and lung injury: 1, 2, 3, 4
    • low income and lung tissue: 1
    • low income and lymph node: 1, 2